• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Research Programs

Research Programs

Research Programs

  • Clinical Trials
  • Faculty Labs
    • Dr. Corey Arnold Lab
      • Meet Our Team
      • Publications
    • Dr. Paul Boutros Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. Jeremie Calais Lab
      • Research Areas
      • Meet Our Team
      • Publications
      • Videos
    • Dr. Karim Chamie Lab
      • Meet Our Team
      • Publications
    • Dr. Andrew Goldstein Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. William Hsu Lab
      • Meet Our Team
      • Publications
    • Dr. Amar Kishan Research
      • Publications
    • Drs. Lueckerath/Mona Lab
      • Meet Our Team
      • Publications
    • Dr. Leonard S Marks Lab
      • Meet Our Team
      • Publications
    • Dr. Robert Reiter Lab
      • Meet Our Team
      • Publications
    • Dr. Lily Wu Lab
      • Meet Our Team
      • Publications
  • Bladder Cancer
  • Kidney Cancer
    • Unique Tumor Repository Launched
  • Prostate Cancer
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • External Funding Opportunities
  • Webinars / Videos
  • Clinical Trials
  • Faculty Labs
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • External Funding Opportunities
  • Webinars / Videos
  • Dr. Corey Arnold Lab
  • Dr. Paul Boutros Lab
  • Dr. Jeremie Calais Lab
  • Dr. Karim Chamie Lab
  • Dr. Andrew Goldstein Lab
  • Dr. William Hsu Lab
  • Dr. Amar Kishan Research
  • Drs. Lueckerath/Mona Lab
  • Dr. Leonard S Marks Lab
  • Dr. Robert Reiter Lab
  • Dr. Lily Wu Lab
  • Research Areas
  • Meet Our Team
  • Publications
  • Videos
  1. Home
  2. Institute of Urologic Oncology
  3. Research Programs
  4. Faculty Labs
  5. Dr. Jeremie Calais Lab

Dr. Jeremie Calais Lab

Share this

Theranostics Clinical Research Program, Jeremie Calais, MD, MSc

Theranostics is the combination of tumor-specific targeted radionuclide imaging and therapy.

The Ahmanson Translational Theranostics Division (ATTD) is a Division of the Department of Molecular and Medical Pharmacology (DMMP). The Division includes the Nuclear Medicine clinic, the Biomedical Cyclotron, as well as basic and translational research groups and labs. Fueled by the adoption of Positron Emission Tomography (PET/CT) and stimulated by major new Theranostics and therapeutic opportunities in prostate cancer and neuroendocrine tumors, the Division and Nuclear Medicine clinic has expanded significantly. Novel therapeutic approaches, together with advanced molecular imaging assays, have given rise to the field of Theranostics, the combination of tumor-specific targeted radionuclide imaging and therapy. Very specific clinical and research expertise is now required to master all aspects of Nuclear Medicine, Molecular Imaging and Theranostics.

Dr. Jeremie Calais MD MSc has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. The clinical research program focuses on translatable radiolabeled theranostic pairs that can be used and applied for diagnosis and therapy of cancer. We collaborate closely with clinical faculty across many departments at UCLA (Urology, Radiation Oncology, Radiology, Medical Oncology, Oncologic Surgery) but also with multiple national and international collaborators. Our group has submitted jointly with UCSF an academic NDA for 68Ga-PSMA-11, a major achievement for academia.

Research Areas >  | Publications > | Meet Our Team > | Videos >


Paul

Jeremie Calais MD MSc

Dr. Jeremie Calais is Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. He is also a member of the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He was mentored by Dr. Johannes Czernin and is now one of the leading prostate cancer imaging and theranostics researchers. He leads the clinical theranostics research program at UCLA that combines radionuclide therapy and imaging. He now serves as Principal Investigator of randomized prospective phase 2 and 3 clinical trials


Figure 1: Examples of pioneering publications in PSMA related Theranostics research

Paul

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest